(Q41648105)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9376669%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

review article

1 reference

title

Donor leukocyte infusions (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9376669%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

11 Donor leukocyte infusions (English)

1 reference

https://api.crossref.org/works/10.1016/S0950-3536(97)80012-1

25 November 2024

author name string

S. Mackinnon

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9376669

25 November 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=9376669

25 November 2024

publication date

1 June 1997

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9376669%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

June 1997

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=9376669

full work available at URL

25 November 2024

https://api.elsevier.com/content/article/PII:S0950353697800121?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0950-3536(97)80012-1

https://api.elsevier.com/content/article/PII:S0950353697800121?httpAccept=text/plain

25 November 2024

1 reference

https://api.crossref.org/works/10.1016/S0950-3536(97)80012-1

Best Practice and Research: Clinical Haematology

25 November 2024

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9376669%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9376669%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9376669%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

page(s)

357-367

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9376669%20AND%20SRC:MED&resulttype=core&format=json

Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation

7 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980012-1

7 January 2021

Selective depletion of CD8+ cells for prevention of graft-versus-host disease after bone marrow transplantation. A randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980012-1

7 January 2021

Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980012-1

7 January 2021

Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980012-1

7 January 2021

Frequency of anti-recipient alloreactive helper T-cell precursors in donor blood and graft-versus-host disease after HLA-identical sibling bone-marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980012-1

7 January 2021

Host-specific interleukin-2-secreting donor T-cell precursors as predictors of acute graft-versus-host disease in bone marrow transplantation between HLA-identical siblings

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980012-1

7 January 2021

Antileukemic Effect of Graft-versus-Host Disease in Human Recipients of Allogeneic-Marrow Grafts

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980012-1

7 January 2021

Use of recombinant human interleukin-2 in conjunction with bone marrow transplantation as a model for control of minimal residual disease in malignant hematological disorders: I. Treatment of murine leukemia in conjunction with allogeneic bone marro

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980012-1

7 January 2021

Clonal origin of chronic myelocytic leukemia in man

8

1 reference

https://api.crossref.org/works/10.1016/S0950-3536(97)80012-1

Adoptive immunotherapy for recurrent CML after BMT

25 November 2024

11

1 reference

https://api.crossref.org/works/10.1016/S0950-3536(97)80012-1

Prediction of graft versus host disease by frequency analysis of cytotoxic T cells after unrelated donor bone marrow transplantation

25 November 2024

16

1 reference

https://api.crossref.org/works/10.1016/S0950-3536(97)80012-1

Graft-versus-host reaction spares normal stem cells in chronic myelogenous leukemia

25 November 2024

20

1 reference

https://api.crossref.org/works/10.1016/S0950-3536(97)80012-1

Polymerase chain reaction is highly predictive of relapse in patients following T cell-depleted allogeneic bone marrow transplantation for chronic myeloid leukemia

25 November 2024

24

1 reference

https://api.crossref.org/works/10.1016/S0950-3536(97)80012-1

Second HLA-identical sibling transplants for leukemia recurrence

25 November 2024

25

1 reference

https://api.crossref.org/works/10.1016/S0950-3536(97)80012-1

25 November 2024

Identifiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9376669%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

1 reference